S4.3-14. Knopp RH, d Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in sub- jects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabe- tes mellitus (ASPEN). Diabetes Care. 2006;29:1478 85. S4.3-15. Mulnier HE, Seaman HE, Raleigh VS, et al. Risk of myocardial infarc- tion in men and women with type 2 diabetes in the UK: a cohort study using the General Practice Research Database. Diabetologia. 2008;51:1639 45. S4.3-16. Rana JS, Liu JY, Moffet HH, et al. Diabetes and prior coronary heart disease are not necessarily risk equivalent for future coronary heart disease events. J Gen Intern Med. 2016;31:387 93. S4.3-17. Sever PS, Poulter NR, Dahl f B, et al. Reduction in cardiovascular events with atorvastatin in 2 532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm (ASCOT-LLA). Diabetes Care. 2005;28:1151 7. S4.3-18. Soedamah-Muthu SS, Fuller JH, Mulnier HE, et al. High risk of cardio- vascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care. 2006;29:798 804. S4.3-19. Wong ND, Glovaci D, Wong K, et al. Global cardiovascular disease risk assessment in United States adults with diabetes. Diab Vasc Dis Res. 2012;9:146 52. S4.3-20. Besseling J, Hovingh GK, Huijgen R, et al. Statins in familial hyper- cholesterolemia: consequences for coronary artery disease and all- cause mortality. J Am Coll Cardiol. 2016;68:252 60. S4.3-21. Khera AV, Won H-H, Peloso GM, et al. Diagnostic yield and clini- cal utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol. 2016;67:2578 89. S4.3-22. Nanchen D, Gencer B, Muller O, et al. Prognosis of patients with familial hypercholesterolemia after acute coronary syndromes. Circulation. 2016;134:698 709. S4.3-23. 